Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

AI Medicine Could be First to Treat Disease With No Cure in a New Way

Jan 29, 2024 - techtimes.com
Insilico Medicine, an AI biotech company, has begun the first phase of clinical trials for its AI-designed drug, ISM5411, to treat Inflammatory Bowel Disease (IBD). The drug, if approved, would be the first to treat IBD by inhibiting prolyl hydroxylase domain (PHD), a protein that controls genes defending the intestinal barrier. The current IBD medications are anti-inflammatory and require immunosuppression, which can lead to other health risks. ISM5411, an oral drug, is designed to repair and rebuild the intestinal lining, focusing on long-term improvement of the disease.

The AI model used to create the drug was Chemistry42, an AI engine that designs new molecules. Insilico Medicine has developed over 30 novel compounds for various diseases, including cancer and COVID-19, using AI. However, there is currently insufficient evidence to support the claim that AI medicines may save lives, and it may take several years for Insilico's products to reach the market or fail during development.

Key takeaways:

  • Insilico Medicine has entered the first phase of clinical trials for its AI-designed medicine, ISM5411, to treat Inflammatory Bowel Disease (IBD).
  • The drug, if licensed, would be the first to treat IBD by inhibiting prolyl hydroxylase domain (PHD), a protein that controls genes defending the intestinal barrier.
  • The AI model used to create the drug was Chemistry42, which designed and ranked potential compounds, leading to the selection of ISM5411.
  • Insilico Medicine has over 30 novel compounds in development for various diseases, including cancer, neurological disorders, and COVID-19, with some already in clinical phases of development.
View Full Article

Comments (0)

Be the first to comment!